Motivated by this, we investigated the proteomic profile of untreated patients with SPMS and PPMS, effects of natalizumab and methylprednisolone treatment, and associations with IgM OCBs, identifying treatment-responsive biomarkers in PMS and further characterizing the subsets of patients with IgM OCBs. The gene discussed is CD40LG; the disease is secondary progressive multiple sclerosis.